# US 2017/0283816 A1 · RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283816 A1
- Document ID: US20170283816A1
- Status: Published application
- Kind: A1
- Application number: 15/617,814
- Filed: 2017-06-08
- Published: 2017-10-05
- Earliest claimed: 2002-02-20
- Assignees: Sirna Therapeutics, Inc.
- Applicants: Sirna Therapeutics, Inc.
- Inventors: Leonid Beigelman; James McSwiggen; Chandra Vargeese
- Web page: https://patentgrep.com/patent/US20170283816A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07H 21/02: with ribosyl as saccharide radical
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1131: {against viruses}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/8218: {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/53: partially self-complementary or closed
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Y: ENZYMES

## Abstract

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A compound comprising:
(I) a short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human apolipoprotein C-III (ApoC3) gene, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to an ApoC3 RNA, wherein said single-stranded polynucleotide:
i) is about 18 to 20 nucleotides in length;
ii) comprises 10 or more phosphorothioate internucleotide linkages;
iii) comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine, 2′-O-methyl pyrimidine, 2′-deoxy-2′-fluoro pyrimidine, locked nucleic acid (LNA) pyrimidine, 2′-methoxyethoxy (MOE) pyrimidine, or a combination thereof; and
(II) a galactosamine.

### Claim 12 (depends on 11)

The compound of claim 11, wherein the single-stranded polynucleotide comprises 10 or more 2′-deoxy pyrimidines.

### Claim 13 (depends on 11)

The compound of claim 11, wherein the single-stranded polynucleotide comprises one or more 2′-methoxyethoxy (MOE) pyrimidines.

### Claim 14 (depends on 11)

The compound of claim 11, wherein the galactosamine comprises N-acetylgalactosamine which is a mono-antennary galactosamine, bi-antennary galactosamine, or a tri-antennary galactosamine.

### Claim 15 (depends on 11)

The compound of claim 11, wherein the galactosamine is attached at the 5′-end or the 3′-end of the single-stranded polynucleotide.

### Claim 16 (depends on 11)

The compound of claim 11, wherein the single stranded polynucleotide is 20 nucleotides long.

### Claim 17 (depends on 11)

The compound of claim 11, wherein the 10 or more modified pyrimidines comprise 4 or more 2′ deoxy pyrimidines.

### Claim 18

A short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human apolipoprotein C-III (ApoC3) gene, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to a human ApoC3 RNA, wherein said single-stranded polynucleotide:
i) is about 18 to 20 nucleotides in length;
ii) comprises 10 or more phosphorothioate internucleotide linkages;
iii) comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine, 2′-O-methyl pyrimidine, 2′-deoxy-2′-fluoro pyrimidine, 2′-methoxyethoxy (MOE) pyrimidine, or a combination thereof.

### Claim 19 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide further comprises a ligand chosen from a galactosamine or a cholesterol.

### Claim 20 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide further comprises a ligand chosen from a mono-antennary galactosamine, bi-antennary galactosamine, or a tri-antennary galactosamine.

### Claim 21 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide comprises one or more 2′-methoxyethoxy (MOE) pyrimidines.

### Claim 22 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide comprises 1, 2, 3, 4, 5 or more locked nucleic acid (LNA) pyrimidines, wherein said LNA pyrimidines is/are located at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, of the single-stranded polynucleotide.

### Claim 23 (depends on 18)

The siNA molecule of claim 18, wherein the 10 or more modified pyrimidines comprise 4 or more 2′ deoxy pyrimidines.

### Claim 24 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide comprises 10 or more 2′-deoxy nucleotides.

### Claim 25 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide comprises one or more 5-methylcytosines.

### Claim 26 (depends on 18)

The siNA molecule of claim 18, wherein the single-stranded polynucleotide comprises 5 or more 5-methylcytosines.

### Claim 27

A short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human apolipoprotein C-III (ApoC3) gene, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to a human ApoC3 RNA, wherein said single-stranded polynucleotide:
i) is 20 nucleotides in length;
ii) comprises 10 or more phosphorothioate internucleotide linkages; and
iii) comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine, 2′-O-methyl pyrimidine, 2′-deoxy-2′-fluoro pyrimidine, 2′-methoxyethoxy (MOE) pyrimidine, or a combination thereof; and
iv) comprises one or more 5-methylcytosines.

### Claim 28 (depends on 27)

The siNA molecule of claim 27, which comprises 5 or more 5-methylcytosine nucleotides.

### Claim 29 (depends on 27)

The siNA molecule of claim 27, wherein the single-stranded polynucleotide comprises one or more 2′-methoxyethoxy (MOE) pyrimidines.

### Claim 30 (depends on 27)

The siNA molecule of claim 27, wherein the 10 or more modified pyrimidines comprise 4 or more 2′ deoxy pyrimidines.

### Claim 31 (depends on 27)

The siNA molecule of claim 27, wherein the single-stranded polynucleotide comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine or 2′-methoxyethoxy (MOE) pyrimidine, or a combination thereof.
